In vivo activity of 11β-Hydroxysteroid dehydrogenase type 1 in man: Effects of prednisolone and chenodesoxycholic acid

Hormone and Metabolic Research

Volumn 43, Issue 1, 2011, Pages 66-71

  Diederich, S ^a,b   Quinkler, M ^a   Mai, K ^a   Schoneshofer M ^c   Baehr, V ^a   Pfeiffer, A ^a   Oelkers, W ^a,b   Eigendorff, E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Endokrinologikum Berlin Am Gendarmenmarkt   (Germany)

^c MARTIN LUTHER KRANKENHAUS   (Germany)

Author keywords

glucocorticoids; IGF 1; metabolic syndrome; metabolism; selective inhibition

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; CHENODEOXYCHOLIC ACID; CORTISONE ACETATE; DEXAMETHASONE; GLUCOCORTICOID; HYDROCORTISONE; PLACEBO; PREDNISOLONE; PREDNISONE; SOMATOMEDIN C;

ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CROSSOVER PROCEDURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME ACTIVITY; HUMAN; LIVER; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UPREGULATION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADULT; CHOLIC ACIDS; CORTISONE; ENZYME INHIBITORS; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; LIVER; MALE; PREDNISOLONE; YOUNG ADULT;

EID: 78650941564     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0030-1267170     Document Type: Article

References (49)

1. Agarwal MK, Mirshahi M. General overview of mineralocorticoid hormone action. Pharmacol Ther 1999 84 273-326
2. Ballard PL, Carter JP, Graham BS, Baxter JD. A radioreceptor assay for evaluation of the plasma glucocorticoid activity of natural and synthetic steroids in man. J Clin Endocrinol Metab 1975 41 290-304
3. Stewart PM, Krozowski ZS. 11 beta-Hydroxysteroid dehydrogenase. Vitam Horm 1999 57 249-324
4. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER, Monder C. Localisation of 11 beta-hydroxysteroid dehydrogenase - tissue specific protector of the mineralocorticoid receptor. Lancet 1988 2 8618 986-989
5. Ricketts ML, Verhaeg JM, Bujalska I, Howie AJ, Rainey WE, Stewart PM. Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab 1998 83 1325-1335
6. Seckl JR, Walker BR. Minireview: 11beta-hydroxysteroid dehydrogenase type 1 - a tissue-specific amplifier of glucocorticoid action. Endocrinology 2001 142 1371-1376
7. Bahr V, Pfeiffer AF, Diederich S. The metabolic syndrome X and peripheral cortisol synthesis. Exp Clin Endocrinol Diabetes 2002 110 313-318
8. Staab CA, Maser E. 11 -Hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and inflammation. J Steroid Biochem Mol Biol 2010 119 56-72
9. Morton NM. Obesity and corticosteroids: 11β-Hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Mol Cell Endocrinol 2010 316 154-164
10. Cooper MS, Stewart PM. 11β-Hydroxysteroiddehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome and inflammation. J Clin Endocrinol Metab 2009 94 4645-4654
11. Veilleux A, Rheaume C, Daris M, Luu-The V, Tchernof A. Omental adipose tissue type 1 11β-Hydroxysteroid dehydrogenase oxoreductase activity, body fat distribution and metabolic alterations in women. J Clin Endocrinol Metab 2009 94 3550-3557
12. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. A Transgenic Model of Visceral Obesity and the Metabolic Syndrome. Science 2001 294 2166-2170
13. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR, Mullins JJ. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 1997 94 14924-14929
14. Bujalska IJ, Kumar S, Hewison M, Stewart PM. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11beta-hydroxysteroid dehydrogenase. Endocrinology 1999 140 3188-3196
15. Hammami MM, Siiteri PK. Regulation of 11 beta-hydroxysteroid dehydrogenase activity in human skin fibroblasts: enzymatic modulation of glucocorticoid action. J Clin Endocrinol Metab 1991 73 326-334
16. Voice MW, Seckl JR, Edwards CR, Chapman KE. 11 beta-hydroxysteroid dehydrogenase type 1 expression in 2S FAZA hepatoma cells is hormonally regulated: a model system for the study of hepatic glucocorticoid metabolism. Biochem J 1996 317 621-625
17. Quinkler M, Troeger H, Eigendorff E, Maser-Gluth C, Stiglic A, Oelkers W, Bhr V, Diederich S. Enhanced 11beta-hydroxysteroid dehydrogenase type 1 activity in stress adaptation in the guinea pig. J Endocrinol 2003 176 185-192
18. Sai S, Esteves CL, Kelly V, Michailidou Z, Anderson K, Coll AP, Nakagawa Y, Ohzeki T, Seckl JR, Chapman KE. Glucocorticoid regulation of the promoter of 11β-Hydroxysteroid dehydrogenase is indirect and requires CCAAT/enhancer-binding protein- Mol Endocrinol 2008 22 2049-2060
19. Quinkler M, Oelkers W, Diederich S. Clinical implications of glucocorticoid metabolism by 11beta-hydroxysteroid dehydrogenases in target tissues. Eur J Endocrinol 2001 144 87-97
20. Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards CR. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 1995 80 3155-3159
21. Alberts P, Engblom L, Edling N, Forsgren M, Klingstrom G, Larsson C, Rönquist-Nii Y, Ohman B, Abrahmsen L. Selective inhibition of 11β-Hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002 45 1528-1532
22. Barf T, Vallgarda J, Emond R, Haggstrom C, Kurz G, Nygren A, Larwood V, Mosialou E, Axellson K, Olsson R, Engblom L, Edling N, Rönquist-Nii Y, Ohman B, Alberts P, Abrahmsen L. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1. J Med Chem 2002 45 3813-3815
23. Su X, Vicker N, Truselle M, Halem H, Culler MD, Potter BV. Discovery of novel inhibitors of human 11β-Hydroxysteroid dehydrogenase type 1. Mol Cell Endocrinol 2009 301 169-173
24. Hadoke PWF, Iqbal J, Walker BR. Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease. Br J Pharmacol 2009 156 689-712
25. Maeda Y, Naganuma S, Niina I, Shinohara A, Koshimoto C, Kondo K, Chijiiwa K. Effects of bile acids on rat hepatic microsomal type I 11β- Hydroxysteroid dehydrogenase. Steroids 2010 75 164-168
26. Diederich S, Grossmann C, Hanke B, Quinkler M, Herrmann M, Bahr V, Oelkers W. In the search for specific inhibitors of human 11beta-hydroxysteroid- dehydrogenases (11beta-HSDs): chenodeoxycholic acid selectively inhibits 11beta-HSD-I. Eur J Endocrinol 2000 142 200-207
27. Ponz de Leon M, Loria P, Carulli N, Murphy G, Dowling R. Intestinal solubilization, absorption, pharmacokinetics and bioavailability of chenodesoxycholic acid. Eur J Clin Invest 1980 10 261-271
28. Stewart PM, Wallace AM, Atherden SM, Shearing CH, Edwards CR. Mineralocorticoid activity of carbenoxolone: contrasting effects of carbenoxolone and liquorice on 11 beta-hydroxysteroid dehydrogenase activity in man. Clin Sci 1990 78 49-54
29. Mai K, Kullmann V, Bobbert T, Maser-Gluth C, Möhlig M, Bhr V, Pfeiffer AFH, Spranger J, Diederich S. In vivo activity of 11beta- hydroxysteroid- dehydrogenase type 1 and free fatty acids induced insulin resistance. Clin Endocrinol 2005 63 442-449
30. Mai K, Andres J, Bobbert T, Maser-Gluth C, Möhlig M, Bhr V, Pfeiffer AFH, Spranger J, Diederich S. Rosiglitazone decreases 11beta-hydroxysteroid- dehydrogenase type 1 in subcutaneous adipose tissue. Clin Endocrinol 2007 67 419-425
31. Otto B, Tschoep M, Heldwein W, Pfeiffer AFH, Diederich S. Endogenous and exogenous glucocorticoids decrease plasma ghrelin in humans. Eur J Endocrinol 2004 151 113-117
32. Diederich S, Hanke B, Burkhardt P, Müller M, Schöneshöfer M, Bhr V, Oelkers W. Metabolism of synthetic corticosteroids by 11β-Hydroxysteroid-dehydrogenases in man. Steroids 1998 63 271-277
33. Diederich S, Eigendorff E, Burkhard P, Quinkler M, Bumke-Vogt C, Rochel M, Seidelmann D, Esperling P, Oelkers W, Bhr V. 11β-Hydroxysteroid dehydrogenase type 1 and 2: An important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J Clin Endocrinol Metab 2002 87 5695-5701
34. Schoneshofer M, Fenner A. A convenient and efficient method for the extraction and fractionation of steroid hormones from serum or urine. J Clin Chem Clin Biochem 1981 19 71-74
35. Ricketts ML, Shoesmith KJ, Hewison M, Strain A, Eggo MC, Stewart PM. Regulation of 11 beta-hydroxysteroid dehydrogenase type 1 in primary cultures of rat and human hepatocytes. J Endocrinol 1998 156 159-168
36. Jamieson PM, Chapman KE, Edwards CR, Seckl JR. 11 beta-hydroxysteroid dehydrogenase is an exclusive 11-reductase in primary cultures of rat hepatocytes: Effect of physiochemical and hormonal manipulations. Endocrinology 1995 136 4754-4761
37. Whorwood CB, Sheppard MC, Stewart PM. Licorice inhibits 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels and potentiates glucocorticoid hormone action. Endocrinology 1993 132 2287-2292
38. Renner E, Horber F, Jost G, Frey BM, Frey FJ. Effect of liver function on the metabolism of prednisone and prednisolone in humans. Gastroenterology 1986 90 819-828
39. Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DE, Johnson O, Walker B. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001 86 1418-1421
40. Moore JS, Monson JP, Kaltsas G, Putignano P, Wood PJ, Sheppard MC, Besser GM, Taylor NF, Stewart PM. Modulation of 11β-Hydroxysteroid dehydrogenase isoenzymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies. J Clin Endocrinol Metab 1999 84 4172-4177
41. Mauras N. Can growth hormone counteract the catabolic effects of steroids? Horm Res 2009 72 48-54
42. Pralong FP, Miell JP, Corder R, Gaillard RC. Dexamethasone treatment in man induces changes in 24-hour growth hormone (GH) secretion profile without altering total GH released. J Clin Endocrinol Metab 1991 73 1191-1196
43. van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 2009 39 81-93
44. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR, Mullins JJ. Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 2004 101 7088-7093
45. Dötsch J, Rascher W. The role of 11β-Hydroxysteroid dehydrogenase activity in the etabolic syndrome: lessons learned from the animal model. Eur J Endocrinol 2002 146 603-605
46. Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes care 2008 31 2383-2390
47. Gambertoglio JG, Vincenti F, Feduska NJ, Birnbaum J, Salvatierra O Jr, Amend WJ. Prednisolone disposition in cushingoid and non cushingoid kidney transplant patients. J Clin Endocrinol Metab 1980 51 561-565
48. Stewart PM, Boulton A, Kumar S, Clark PMS, Shackleton CHL. Cortisol metabolism in human obesity: impaired cortisone to cortisol conversion in subjects with central obesity. J Clin Endocrinol Metab 1999 84 1022-1027
49. Andrews RC, Herlihy O, Livingstone DE, Andrew R, Walker BR. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. J Clin Endocrinol Metab 2002 87 5587-5593